We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

CAMCI: Advancing the Use of Computerized Screening in Healthcare

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03512301
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : August 3, 2022
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Amy Eschman, Psychology Software Tools, Inc.

Brief Summary:
Cognitive impairment is a significant health problem in the United States, resulting in costs over $100 billion a year. We will provide an efficient, effective, and financially intelligent solution to Primary Care Physician's to identify cognitive impairment in the earliest stages, delay progression through appropriate treatment, and to afford patients the opportunity to make future plans at a time when symptoms are mild and patients are able to make informed decisions concerning financial and life activities. This has the potential to delay devastating effects of cognitive impairment, and to lessen the financial burden on the health care system in the United States.

Condition or disease Intervention/treatment Phase
Cognitive Dysfunction Cognitive Impairment Cognitive Decline Cognitive Change Device: CAMCI Not Applicable

Detailed Description:
Cognitive dysfunction in the elderly population, ranging from simple forgetfulness to a diagnosis of Alzheimer's disease, can impact one's quality of life and ability to function in daily activities. It is crucial that decline be detected as early as possible in order to evaluate whether the cause is treatable, and to employ appropriate treatment, if applicable. The majority of older patients rely on their primary care physician for the bulk of their healthcare needs, but there is a lack of sensitive tools available, and there is a lack of physician's time to use the tools, leading to a failure to provide therapeutic intervention at the earliest stages of loss to potentially slow the progression of disease. Psychology Software Tools, Inc. (PST) has developed the Computer Assessment of Memory and Cognitive Impairment (CAMCI), a computerized screening tool for detection of early signs of cognitive decline, which has been shown to be more effective in the identification of patients with subtle cognitive loss than the tools most frequently used within the primary care physician (PCP) office. CAMCI would provide an option for PCPs and clinicians to provide therapeutic intervention prior to a diagnosis of dementia. Recent additions to Current Procedural Terminology (CPT) codes permit insurance reimbursement for neuropsychological testing by a computer, including time for the physician's or clinical psychologist's interpretation and reporting. The introduction of this new revenue stream for PCPs and clinicians, coupled with the characteristics of being brief and self-administered make CAMCI an attractive option for improving early intervention, providing an intelligent business solution for healthcare professionals, and a useful and effective tool that allows physicians to better evaluate and serve their patients. The specific aims included in the current project focus on activities required to successfully move CAMCI to commercialization by extending support for late stage research and product development, including regulatory strategy and intellectual property development, data collection to replicate key studies, product extension through increasing minority representation, and development of a measure of meaningful change. The ultimate goal is to streamline commercialization of CAMCI, and to provide a useful and effective tool in the detection of cognitive dysfunction to physicians, the providers of the majority of healthcare to the elderly population, to improve efficiency and effectiveness of clinical practice.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 820 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: CAMCI: Advancing the Use of Computerized Screening in Healthcare
Actual Study Start Date : August 8, 2019
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : May 31, 2023

Arm Intervention/treatment
Experimental: CAMCI Baseline Only
Computerized and paper-pencil neuropsychological tests, baseline
Device: CAMCI
CAMCI battery of computerized tasks
Other Name: CAMCI task battery

Experimental: CAMCI Baseline + Follow-Up
Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
Device: CAMCI
CAMCI battery of computerized tasks
Other Name: CAMCI task battery

Primary Outcome Measures :
  1. Agreement to reference standard [ Time Frame: baseline ]
    Comparison (positive and negative percent agreement, confidence interval estimates, and quadratic weighted kappa) between CAMCI classifications and clinical adjudication classifications

  2. Agreement to non-reference standard [ Time Frame: baseline ]
    Linear regression agreement analysis (scatterplot, linear regression equation and confidence intervals, and Pearson correlation) between CAMCI score and Montreal Cognitive Assessment (MoCA) score.

Secondary Outcome Measures :
  1. Criterion validity correlation analysis [ Time Frame: baseline ]
    Analysis of correlations between CAMCI accuracy measures (i.e., accuracy of responses within individual tasks) and individual paper and pencil neuropsychological tests (i.e., scores achieved on individual tests) to assess both convergent (high correlations with related measures) and divergent (lower correlations with measures that should not be related) validity.

  2. Test/retest reliability [ Time Frame: 2-3 weeks ]
    Repeatability of CAMCI

Other Outcome Measures:
  1. Measure of significant change [ Time Frame: baseline, 6 months, 12 months, 24 months post baseline ]
    To develop a measure of significant change, we will compare overall CAMCI scores (calculated as the sum of the individual task scores) to expected scores (based on age and education) across repeated assessments (baseline, and 6,12, and 24 months from baseline) using a Reliable Change Index (RCI) method, as well as within-subject standard deviation using a one-way analysis of variance model.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed informed consent
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Able to read, write and understand study and test requirements
  • Within the age range of 60+

Exclusion Criteria:

  • Significant neurologic disease, such as multi-infarct dementia, Parkinson's disease, epilepsy, stroke, multiple sclerosis or head trauma
  • History of major depression or other major psychiatric disorder, such as, schizophrenia and bipolar disorder
  • History of consuming 5 or more alcoholic drinks per day on a regular basis
  • MoCA score <10

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03512301

Layout table for location contacts
Contact: Michelle Fouse 412-449-0078 michelle.fouse@pstnet.com
Contact: Amy Eschman 412-449-0078 amy.eschman@pstnet.com

Layout table for location information
United States, Indiana
Indiana University Active, not recruiting
Indianapolis, Indiana, United States, 46202
United States, Pennsylvania
Psychology Software Tools Active, not recruiting
Sharpsburg, Pennsylvania, United States, 15215
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Adriana Strutt    713-798-8673    adrianam@bcm.edu   
Contact: Donna Talavari       donna.talavari@bcm.edu   
Principal Investigator: Adriana Strutt, PhD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22904
Contact: Lisa Opie    434-243-5143    RBO5N@hscmail.mcc.virginia.edu   
Contact: Hillary Perez    434-924-0453    HYP8Q@hscmail.mcc.virginia.edu   
Sub-Investigator: Carol Manning, PhD         
Sponsors and Collaborators
Psychology Software Tools, Inc.
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Amy Eschman Psychology Software Tools
Layout table for additonal information
Responsible Party: Amy Eschman, Grants Administration Manager, Psychology Software Tools, Inc.
ClinicalTrials.gov Identifier: NCT03512301    
Other Study ID Numbers: 13
2SB1AG037357-04A1 ( U.S. NIH Grant/Contract )
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Quality-controlled raw data as well as processed data used in publications will be made available. Shared data will include computerized task scores, neuropsychological test scores, and full analytical codes used to process and analyze the data. Workflows will be described and documented to allow replication of results from the raw data.

Data and corresponding documentation will be made available through Open Science Framework (https://osf.io/), in addition to any potential requirements on software sharing by journals.

The PI or Co-Investigators will disseminate results from this research through presentations at public lectures, scientific institutions and meetings, and/or publication in major journals. The PI and Co-Investigators will adhere to the NIH Grants Policy on Sharing of Unique Research Resources including the Sharing of Biomedical Research Resources: Guidelines for Recipients of NIH Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.

Supporting Materials: Study Protocol
Analytic Code
Time Frame:

Data will be deposited into the repository indicated above as soon as possible, but no later than 4 years after the end of the award project period.

The Small Business Act provides authority for NIH to protect from disclosure and nongovernmental use all Small Business Innovative Research (SBIR) data developed from work performed under an SBIR funding agreement for a period of 4 years after the closeout of either a phase I or phase II grant unless NIH obtains permission from the awardee to disclose these data. The data rights protection period lapses only upon expiration of the protection period applicable to the SBIR award, or by agreement between the small business concern and NIH.

Access Criteria: PST will identify where the data will be available and how to access the data in any publications and presentations about these data, as well as acknowledge the repository and funding source in any publications and presentations. In addition, PST will abide by the policies and procedures required by the repository indicated above, fully consistent with NIH data sharing policies and applicable laws and regulations.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders